Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Back

Impact of Severe Acute Respiratory Syndrome (SARS-CoV-2/COVID-19) Related Pneumonia on Lung Function and Structure.

NCT04916834·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

National Institute for Tuberculosis and Lung Diseases, Poland

With

Medical University of Warsaw

Objective: Assessment of pulmonary and heart dysfunction, fibrosis-related markers and antibodies as well as the search for risk factors for an unfavorable course and possible complications in patients after pneumonia due to SARS-CoV-2 (COVID-19) infection. Patients: A group of approx. 100 patients assessed shortly after pneumonia and followed up, investigated after 3 and 6 months with possible prolongation to 12 months.

Age

18–100

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

1. Confirmed SARS-CoV-2 infection with pneumonia hospitalized
2. Two negative PCR results of a swab from the respiratory tract in succession, including the last one taken no later than 3 days before the planned lung function tests (1st visit).

You may not be if

1. Lack of patient consent,
2. Present contraindications for lung function tests
3. Inability to perform correctly lung function measurements

The record

StatusUnknown

PhaseNo phase

Taking part100

StartedAug 2020

UpdatedFeb 23, 2023

Conditions

Covid19 SARS-CoV Infection Pulmonary Function Pneumonia, Viral

Where1

National Institute for Tuberculosis and Lung Diseases
Warsaw, Masovian Voivodeship, Poland

Clareo Health | Impact of Severe Acute Respiratory Syndrome (SARS-CoV-2/COVID-19) Related Pneumonia on Lung Function and Structure.